CVE:BTI Bioasis Technologies (BTI) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free BTI Stock Alerts C$0.0050 -0.01 (-50.00%) (As of 03/18/2024) Add Compare Share Share Today's RangeC$0.01▼C$0.0150-Day RangeC$0.01▼C$0.0152-Week RangeC$0.01▼C$0.03Volume5,249 shsAverage Volume73,137 shsMarket CapitalizationC$397,050.00P/E RatioN/ADividend Yield40,400.00%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Bioasis Technologies alerts: Email Address Ad Stansberry ResearchSee this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) Click here to see it. About Bioasis Technologies Stock (CVE:BTI)Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.Read More BTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTI Stock News HeadlinesMarch 27, 2024 | seekingalpha.comRBT Rubicon Technologies, Inc.February 21, 2024 | theglobeandmail.comBioasis Technologies: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (BTI)April 25, 2024 | Chaikin Analytics (Ad)Wall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.February 16, 2024 | morningstar.comBioasis Technologies Inc BIOAFOctober 29, 2023 | theglobeandmail.comBioasis Technologies: Top 10 Undervalued Biotechnology Industry Stocks (BTI)August 4, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc down on Friday (BTI)July 19, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc flat on Tuesday (BTI)June 20, 2023 | technews.tmcnet.comBioasis Provides Corporate Update and Announces Suspension of OperationsApril 25, 2024 | Chaikin Analytics (Ad)Wall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.June 7, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc down on Monday (BTI)May 17, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc down on Tuesday (BTI)May 15, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc up on Monday (BTI)May 11, 2023 | theglobeandmail.comBioasis Technologies: Bottom 25 Performing Stocks Year-to-Date on TSX-V (BTI)May 5, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc flat on Thursday (BTI)May 5, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc down on Wednesday (BTI)April 29, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc flat on Friday (BTI)April 28, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc down on Thursday (BTI)April 18, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc flat on Monday (BTI)April 7, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc flat on Wednesday (BTI)February 3, 2023 | finance.yahoo.comBioasis Announces AGM Results and Provides Update on Financial PositionDecember 19, 2022 | lse.co.ukAIM WINNERS & LOSERS: Midatech shares soar on Bioasis acquisitionDecember 19, 2022 | marketwatch.comMidatech Pharma Shares Rise on Revised Placement Terms, Intention to Remain on AIMDecember 14, 2022 | ca.finance.yahoo.comBioasis Technologies Inc. Announces Shareholder WebinarOctober 12, 2022 | reuters.comBioasis Technologies IncJuly 28, 2022 | finance.yahoo.comBIOAF: FY 2022 Results and Valuation UpdateMay 10, 2022 | stockhouse.comBioasis and Neuramedy Enter into Research Collaboration and License AgreementMarch 9, 2022 | finance.yahoo.comBioasis to Attend and Present at Upcoming Industry ConferenceSee More Headlines Receive BTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioasis Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:BTI CUSIPN/A CIKN/A Webwww.bioasis.ca Phone+1-604-2957014FaxN/AEmployees55,329Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-2,880,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-80.58% Debt Debt-to-Equity Ratio27.88 Current Ratio0.11 Quick Ratio0.17 Sales & Book Value Annual SalesC$158,165.00 Price / Sales2.51 Cash FlowC$0.00 per share Price / Cash Flow13.57 Book ValueC($0.03) per share Price / Book-0.17Miscellaneous Outstanding Shares79,410,000Free FloatN/AMarket CapC$397,050.00 OptionableNot Optionable Beta0.42 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Deborah Ann Rathjen B.Sc. (Hons.) (Age 66)FTSE, M.A.I.C.D., Ph.D., Q.C., Executive Chairman, CEO & President Comp: $208.8kMr. David P. Jenkins (Age 62)Chief Financial Officer Comp: $125.28kMr. Graeme DickDirector of Investor RelationsMr. Aaron EltonDirector of MarketingDr. Mei Mei TianVP & Head of External ResearchKey CompetitorsCotinga Pharmaceuticals Inc. (COT.V)CVE:COTiCo TherapeuticsCVE:ICOPascal BiosciencesCVE:PASSolarvest BioEnergyCVE:SVSAvivagenCVE:VIVView All Competitors BTI Stock Analysis - Frequently Asked Questions How have BTI shares performed in 2024? Bioasis Technologies' stock was trading at C$0.01 at the beginning of the year. Since then, BTI stock has increased by 0.0% and is now trading at C$0.01. View the best growth stocks for 2024 here. Is Bioasis Technologies a good dividend stock? Bioasis Technologies (CVE:BTI) pays an annual dividend of C$2.02 per share and currently has a dividend yield of 1.50%. What other stocks do shareholders of Bioasis Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioasis Technologies investors own include Praxair (PX), Organigram (OGI), Morningstar (MORN), Five Below (FIVE), Extendicare (EXE), Trees (CANN), Blackstone Mortgage Trust (BXMT) and Bank of America (BAC). How do I buy shares of Bioasis Technologies? Shares of BTI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:BTI) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioasis Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
